期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氯吡格雷抵抗的研究进展 被引量：9

原文传递
导出
摘要 氯吡格雷是第二代二磷酸腺苷(ADP)受体拮抗剂,它可与血小板表面ADP受体P2Y12结合进而抑制ADP诱导的血小板聚集。联合氯吡格雷与阿司匹林的双联抗血小板治疗(DAPT)可显著降低冠心病患者的心血管事件。然而,氯吡格雷的疗效存在显著的个体差异,部分患者在DAPT的基础上仍发生急性心肌梗死、支架内血栓等事件。本文就氯吡格雷抵抗(CR)的概念、原因、防治等相关研究作一综述。
作者 刘洁 李春坚
机构地区 南京医科大学第一附属医院心脏病科
出处 《江苏医药》 CAS 北大核心 2013年第15期1814-1816,共3页 Jiangsu Medical Journal
基金 国家自然科学基金(81170181)
关键词 氯吡格雷抵抗 冠心病患者 抗血小板治疗 急性心肌梗死 受体拮抗剂 二磷酸腺苷 血小板聚集 ADP诱导
分类号 R541 [医药卫生—心血管疾病]
  • 相关文献

参考文献15

  • 1Simon T, Verstuyft C, Mary-Krause M, et al. Genetic deter-minants of response to clopidogrel and cardiovascular events[J]. N Engl J Med,2009,360(4) :363-375.
  • 2Silva FB,Almeida Junior GL,Neno A, et al. Resistanceto clopidogrel j prevalence and associate variables[J]. Arq BrasCardiol,2012,99(6) :1135-1141.
  • 3Guthikonda S,Alviar CL, Vaduganathan M, et al. Roleof reticulated platelets and platelet size heterogeneity onplatelet activity after dual antiplatelet therapy with aspirinand clopidogrel in patients with stable coronary artery disease[J]. J Am Coll Cardiol,2008,52(9) :743-749.
  • 4Muller I, Besta F, Schulz C,et al. Prevalence of clopidogrelnon-responders among patients with stable angina pectorisscheduled for elective coronary stent placement [J], ThrombHaemost,2003,89(5) : 783-787.
  • 5Bonello L, Tantry US, Marcucci R, et al. Consensus andfuture directions on the definition of high on-treatmentplatelet reactivity to adenosine diphosphate [J]. J Am CollCardiol,2010,56(12) :919-933.
  • 6Tang XF, Wang J.Zhang JH,et al. Effect of the CYP2C19 * 2and * 3 genotypes, ABCB1 C3435T and PON1 Q192R alleleson the pharmacodynamics and adverse clinical events ofclopidogrel in Chinese people after percutaneous coronaryintervention[J]. Eur J Clin Pharmacol, 2013,69(5): 1103-1112.
  • 7Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with orwithout omeprazole in coronary artery disease [J]. N Engl JMed,20l0,363(20):1909-1917.
  • 8Kwok CS, Jeevanantham V, Dawn B, et al. No consistentevidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel : Meta-analysis[J]. Int J Cardiol,2012. [Epub ahead of print].
  • 9Levine GN, Bates ER,Blankenship JC. et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Interven-tion :a report of the American College of Cardiology Founda-tion/ American Heart Association Task Force on PracticeGuidelines and the Society for Cardiovascular Angiographyand Interventions[J]. Circulation,2011,124(23) : 574-651.
  • 10Aradi D,Rideg 0,Vorobcsuk A,et al. Justification of 150 mgclopidogrel in patients with high on-clopidogrel platelet reac-tivity[J]. Eur J Clin Invest,2012,42(4) :384-392.

二级参考文献10

  • 1Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery ( EACTS ), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J,2010 , 31:2501-2555.
  • 2Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation, 2011, 124 :e574-651.
  • 3Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coil Cardiol, 2011,58 :e123-210.
  • 4Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation ( EuroSCORE ). Eur J Cardiothorac Surg, 1999,16:9-13.
  • 5Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009,360:961- 972.
  • 6Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coil Cardiol,2010,55:1923-1932.
  • 7Online STS fish calculator [ S/OL]. [ 2012-01-01 ]. http:// riskcalc, sts. org/STSWebRiskCalc273/de, aspx.
  • 8Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes ( CURRENT-OASIS 7 ): a randomised factorial trial. Lancet,2010,376 : 1233-1243.
  • 9Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Cell Cardiol,2007,50 : 1742-1751.
  • 10Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation, 2011,123:2736-2747.

共引文献424

同被引文献74

  • 1Gergely Feher,Andrea Feher,Gabriella Pusch,Katalin Koltai,Antal Tibold,Beata Gasztonyi,Elod Papp,Laszlo Szapary,Gabor Kesmarky,Kalman Toth.Clinical importance of aspirin and clopidogrel resistance[J].World Journal of Cardiology,2010,2(7):171-186. 被引量：36
  • 2Jawahar L Mehta,Bhavna Mohandas.Aspirin resistance: Fact or fiction? A point of view[J].World Journal of Cardiology,2010,2(9):280-288. 被引量：7
  • 3辛晓敏,金英玉,张云平,关秀茹,李洁.阿司匹林抵抗与尿11-脱氢-血栓素B_2的检测及相关性研究[J].中华检验医学杂志,2005,28(9):919-921. 被引量：10
  • 4各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量：33020
  • 5Longstreth K L, Wertz jr R, et al. High-dose clopidogrel loading in percutaneous coronary intervention [J]. Ann Pharmaco ther, 2005,39:918- 922.
  • 6Von Beckerath N, Taubert D, Pogatsam Urray G, et al. Ab- sorption, metabolization, and antiplatelet effects of 300-, 600-, and 900mg loading doses of clopidogrel. Results of the ISAR- CHOICE (intracoronary stenting and antithrombotic regimen: Choose between 3 high oral doses for immediate clopidogrel effect) Trial [J]. Circulation, 2005,112:2946- 2950.
  • 7Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periproeedural myo- cardial infarction in patients undergoing coronary intervention: results from the ARM YDA- 2 (Antiplatelet therapy for reduc- tion of myocardial damage during angioplasty) study [J]. Circu- lation, 2005, 111: 2099-2106.
  • 8Gratsianskii N A. Clopidogrel should be added to aspirin for at least 1 year after percutaneous coronary interventions (CREDO) while before them its loading dose can reach 600 mg (ISAR- COOL)[J]. Kardiologiia, 2003,43 : 71-73.
  • 9Bonello L, Tantry US, Mareueci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[ J]. J Am Coll Cardiol, 2010, 56(12) : 919-933.
  • 10Brunton LL, Chabner B, Goodman LS, et al. Goodman and gil- man's the pharmacological basis of therapeutics [ M ]. 12th ed. New York: McGraw-Hill, 2011: 1483- 1488.

引证文献9

二级引证文献35

江苏医药
2013年 第15期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部